These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19300145)

  • 41. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
    Yoon JS; Kim JC; Lee SY
    Korean J Ophthalmol; 2009 Sep; 23(3):137-41. PubMed ID: 19794937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm.
    Kalra HK; Magoon EH
    Ophthalmic Surg; 1990 May; 21(5):335-8. PubMed ID: 2381655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Supramaximal doses of botulinum toxin for refractory blepharospasm.
    Levy RL; Berman D; Parikh M; Miller NR
    Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complications of Preseptal Versus Pretarsal Botulinum Toxin Injection in Benign Essential Blepharospasm: A Randomized Controlled Trial.
    Sanguandikul L; Apinyawasisuk S; Jariyakosol S; Hirunwiwatkul P; Chongpison Y
    Am J Ophthalmol; 2021 Dec; 232():9-16. PubMed ID: 33965414
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin type a and its uses in dry eye disease.
    Victoria AC; Pino A
    Plast Reconstr Surg; 2012 Jul; 130(1):209e-210e. PubMed ID: 22743932
    [No Abstract]   [Full Text] [Related]  

  • 46. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Safety and efficacy of botulinum toxin in hemifacial spasm].
    Mazlout H; Kamoun Gargouri H; Triki W; Kéfi S; Brour J; El Afrit MA; Chéour M; Kraiem A
    J Fr Ophtalmol; 2013 Mar; 36(3):242-6. PubMed ID: 23270989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.
    Arat YO; Yen MT
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):22-4. PubMed ID: 17237684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial.
    Mezaki T; Kaji R; Brin MF; Hirota-Katayama M; Kubori T; Shimizu T; Kimura J
    Mov Disord; 1999 Nov; 14(6):1017-20. PubMed ID: 10584680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
    Lee S; Park S; Lew H
    Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement in pelvic pain with botulinum toxin type A - Single vs. repeat injections.
    Nesbitt-Hawes EM; Won H; Jarvis SK; Lyons SD; Vancaillie TG; Abbott JA
    Toxicon; 2013 Mar; 63():83-7. PubMed ID: 23220489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oculinum injection-resistant blepharospasm in young patients.
    Roggenkämper P; Nüssgens Z
    Ophthalmic Plast Reconstr Surg; 1997 Mar; 13(1):73. PubMed ID: 9076788
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Botulinum Toxin A Treatment on Eyelid Pressure in Eyes with Blepharospasm.
    Namiguchi K; Mizoue S; Ohta K; Shiraishi A
    Curr Eye Res; 2018 Jul; 43(7):896-901. PubMed ID: 29641935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preventing ptosis after botulinum treatment.
    Scott AB
    Ophthalmic Plast Reconstr Surg; 1997 Jun; 13(2):81-3. PubMed ID: 9185190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.